– Immunicon Corporation (NASDAQ:IMMC) announced today that the Nasdaq Stock Market has approved its application to transfer the listing of its common stock to the Nasdaq Capital Market. Immunicon’s common stock began trading on the Nasdaq Capital Market, and ceased trading on the Nasdaq Global Market, at the opening of business today.
As reported in its press release of
November 16, 2007, Immunicon’s stockholders’ equity fell below the $10 million minimum requirement for continued listing on the Nasdaq Global Market. Immunicon could have sought Nasdaq’s approval of a plan to restore compliance with the $10 million stockholders’ equity requirement, but concluded that doing so was not in Immunicon’s best interest.
About Immunicon Corporation
Immunicon Corporation is developing and commercializing proprietary cell- and molecular-based human diagnostic and life science research products, and is providing certain analytical services to pharmaceutical and biotechnology companies to assist them in developing new therapeutic agents, with an initial focus on cancer disease management. Immunicon has developed platform technologies to identify, count and characterize a small number of rare cells in blood, such as circulating tumor cells and circulating endothelial cells that are important in many diseases and biological processes. Immunicon’s products and underlying technology platforms also have application in cancer research and may have applications in other fields of medicine, such as cardiovascular and infectious diseases. For more information, please visit www.immunicon.com.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often preceded by words such as “hope,” “may,” “believe,” “anticipate,” “plan,” “expect,” “intend,” “assume,” “will” and similar expressions. Forward-looking statements contained in this press release include, among others, statements regarding Immunicon’s continued compliance with the regulations associated with its listing on The Nasdaq Capital Market and other statements not of historical fact. Immunicon cautions investors not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release, are based on the current expectations and intent of the management of Immunicon and involve certain factors, such as risks and uncertainties that may cause actual results to be far different from those suggested by these statements. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict, including, but not limited to, risks and uncertainties associated with: Immunicon’s ability to retain its listing on The Nasdaq Capital Market, Immunicon’s dependence on Veridex, LLC, a Johnson & Johnson company, in the field of cancer cell analysis and the ongoing arbitration proceeding with Veridex; the ability to earn license and milestone payments under Immunicon’s agreement with Veridex; Immunicon’s capital and financing needs; research and development and clinical trial expenditures; commercialization of product candidates; Immunicon’s ability to obtain licenses from third parties to commercialize products; Immunicon’s ability to manage its growth; obtaining necessary regulatory approvals; reliance on third party manufacturers and suppliers; reimbursement by third party payors to Immunicon’s customers; compliance with applicable manufacturing standards; retaining key personnel; delays in the development of new products or planned improvements to products; effectiveness of products compared to competitors’ products; protection of Immunicon’s intellectual property; conflicts with third party intellectual property; product liability lawsuits that may be brought against Immunicon; labor, contract or technical difficulties; and competitive pressures in Immunicon’s industry. These factors are discussed in more detail in Immunicon’s filings with the Securities and Exchange Commission. Except as required by law, Immunicon accepts no responsibility for updating the information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise, or for modifications made to this document by Internet or wire services.
“Immunicon” and the Immunicon Corporation logo are registered trademarks of Immunicon Corporation. ALL RIGHTS RESERVED.
Immunicon Corporation
James G. Murphy
SVP of Finance & Administration, CFO
215-346-8313
jmurphy@immunicon.com
or
Investors/Media:
Tierney Communications
Denise Portner
Vice President
215-790-4395
dportner@tierneyagency.com